- Home
- Publications
- Publication Search
- Publication Details
Title
Ipilimumab for the treatment of metastatic prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 2, Pages 205-213
Publisher
Informa UK Limited
Online
2017-12-22
DOI
10.1080/14712598.2018.1420777
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Micrornas in prostate cancer: an overview
- (2017) Daniela Vanacore et al. Oncotarget
- Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells
- (2017) Cinzia Borghese et al. Oncotarget
- Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
- (2017) Liting Guo et al. Journal of Cancer
- Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
- (2017) Jennifer Kalina et al. Cancers
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
- (2016) Valerio Nardone et al. CANCER BIOLOGY & THERAPY
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- (2016) Frank B. Cortazar et al. KIDNEY INTERNATIONAL
- Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
- (2016) Mark J. Selby et al. PLoS One
- Inducible expression of cancer-testis antigens in human prostate cancer
- (2016) Erika Heninger et al. Oncotarget
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- A Perspective of Immunotherapy for Prostate Cancer
- (2016) Ida Silvestri et al. Cancers
- miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer
- (2016) Zhigang Wang et al. Scientific Reports
- Combining Immunotherapy and Radiation for Prostate Cancer
- (2015) Steven E. Finkelstein et al. Clinical Genitourinary Cancer
- Taxane anticancer agents: a patent perspective
- (2015) Iwao Ojima et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
- (2015) J Gao et al. ONCOGENE
- Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
- (2015) David I. Quinn et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
- (2015) Gilli Galore-Haskel et al. Oncotarget
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
- (2014) JamesL Gulley et al. ASIAN JOURNAL OF ANDROLOGY
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
- (2014) Yan Feng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer
- (2014) Michael L. Cheng et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Demystifying Immunotherapy in Prostate Cancer
- (2013) Ravi A. Madan et al. CANCER JOURNAL
- Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer
- (2013) Irene Cardillo et al. Future Oncology
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
- (2013) Edward Cha et al. Cancer Medicine
- Circulating Tumor Cells: Liquid Biopsy of Cancer
- (2012) C. Alix-Panabieres et al. CLINICAL CHEMISTRY
- Differential Immunologic and MicroRNA Effects of 2 Dosing Regimens of Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor
- (2012) Pierre L. Triozzi et al. JOURNAL OF IMMUNOTHERAPY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prostate Cancer Immunotherapy: Figure 1.
- (2011) Kenneth F. May et al. CLINICAL CANCER RESEARCH
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started